Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (21-30 of 380) with videos related to

Pageof 38
Sort By:
Current Opinion in Nephrology and Hypertension|September 3, 2011
Renal sympathetic denervation in hypertensionMichael Doumas, Charles Faselis, Vasilios Papademetriou
The American Journal of Cardiology|April 23, 2022
Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
The American Journal of Cardiology|April 6, 2022
Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure IndicesDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
Internal and Emergency Medicine|March 25, 2022
"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" commentDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|March 9, 2022
Meta-Analysis Addressing the Cardiovascular Safety of Daprodustat in Patients With Chronic Kidney Disease Undergoing Dialysis or NotDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Cardiology|May 14, 2015
Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?Michael Doumas, Vasilios Athyros, Asterios Karagiannis
European Journal of Internal Medicine|February 26, 2021
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Polish Archives of Internal Medicine|December 23, 2021
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: considerations on body composition and skeletal massDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Circulation|July 4, 2012
Letter by Triantafyllou et al regarding article, "Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study"Areti Triantafyllou, Panagiota Anyfanti, Michael Doumas
Diabetes, Obesity & Metabolism|December 15, 2020
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trialsDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Pageof 38

Showing results (21-30 of 380) with videos related to

Sort By:
Pageof 38
Current Opinion in Nephrology and Hypertension|September 3, 2011
Renal sympathetic denervation in hypertensionMichael Doumas, Charles Faselis, Vasilios Papademetriou
The American Journal of Cardiology|April 23, 2022
Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
The American Journal of Cardiology|April 6, 2022
Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure IndicesDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
Internal and Emergency Medicine|March 25, 2022
"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" commentDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|March 9, 2022
Meta-Analysis Addressing the Cardiovascular Safety of Daprodustat in Patients With Chronic Kidney Disease Undergoing Dialysis or NotDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Cardiology|May 14, 2015
Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?Michael Doumas, Vasilios Athyros, Asterios Karagiannis
European Journal of Internal Medicine|February 26, 2021
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Polish Archives of Internal Medicine|December 23, 2021
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: considerations on body composition and skeletal massDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Circulation|July 4, 2012
Letter by Triantafyllou et al regarding article, "Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study"Areti Triantafyllou, Panagiota Anyfanti, Michael Doumas
Diabetes, Obesity & Metabolism|December 15, 2020
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trialsDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Pageof 38